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Introduction
Several reports have documented the presence of exces-
sive daytime sleepiness (EDS) with frequent napping
and/or increased sleep time during daytime in a signif-
icant proportion (15–51 %) of patients with idiopathic
Parkinson’s disease (IPD) [1–6].Self-reported EDS as es-
timated by an Epworth sleepiness score (ESS) > 10 has
been found in up to 50 % of patients with IPD, with a fre-
quency of falling asleep while driving in almost half of
them [7]. It is noteworthy that sudden, irresistible, and
overwhelming sleepiness that occurs without warning
(“sleep attacks”) in IPD may also occur in the absence of
abnormal scores on the ESS. The sensitivity and speci-
ficity of an ESS > 10 for the occurrence of “sleep attacks”
have been reported to be 71 % and 88 %, respectively [8].
Excessive daytime sleepiness has also been reported
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■ Abstract Background Parkin-
sonian patients with excessive day-
time sleepiness (EDS), hallucina-
tions, REM sleep behavior disorder
(RBD), short mean sleep latencies,
and sleep-onset REM periods
(SOREMP) on multiple sleep la-
tency tests (MSLT) have been re-
ported. In these patients a nar-
colepsy-like pathophysiology of
sleep-wake disturbances has been
suggested. Patients and methods
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We studied 14 consecutive patients
with Parkinsonism and EDS. Stan-
dard studies included assessment
of duration and severity of Parkin-
sonism (Hoehn & Yahr score), Ep-
worth sleepiness score (ESS), his-
tory of “REM-symptoms”
(RBD/hallucinations/sleep paraly-
sis/cataplexy-like episodes),
polysomnography (PSG), MSLT,
and measurement of cerebrospinal
fluid (CSF) levels of hypocretin-1
(orexin A). Results There were 12
men and 2 women (mean age 69
years; range 54–82). The mean du-
ration and the Hoehn&Yahr score
were 6.3 years and 2.2, respectively.
Diagnoses included idiopathic
Parkinson’s disease (IPD, n = 10),
dementia with diffuse Lewy bodies
(n = 3), and multisystem atrophy
(n = 1). The ESS was ≥10 in all pa-
tients (mean 12; range 10–18).
“REM-symptoms” were reported
by all but two patients (hallucina-
tions: n = 9; RBD: n = 9). None of
the patients reported cataplexy-like
symptoms or sleep paralysis. On
PSG sleep apnea (apnea hypopnea
index > 10/h, n = 7), periodic limb
movements during sleep (PLMS-
index > 10/h, n = 6), and features of
RBD (n = 5) were found. On MSLT
mean sleep latency was < 5 minutes
in 10 patients, and SOREMP were
found in two patients. When com-
pared with controls (n = 20, mean
497 pg/ml; range 350–603), CSF
hypocretin-1 levels were normal in
8 patients and low in 2 patients
(221 and 307 pg/ml, respectively).
Conclusion These findings do not
support the hypothesis of a “ final
common pathway” in the patho-
physiology of narcolepsy and
Parkinsonism with EDS. Sleep ap-
nea and PLMS may play a so-far
underestimated role in the patho-
genesis of EDS in Parkinsonian pa-
tients.
■ Key words Parkinsonism ·
narcolepsy · REM sleep behavior
disorder · hypocretin · excessive
daytime sleepiness · Epworth
sleepiness score · sleep attacks
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in other Parkinsonian disorders such as multisystem at-
rophy (MSA), dementia with Lewy bodies (DLB), and
progressive supranuclear palsy (PSP) [9].
The etiology of EDS in Parkinsonian patients is prob-
ably multifactorial. Potential factors such as age, motor
disability, disturbed nocturnal sleep (caused by sleep
disordered breathing or periodic leg movements), lev-
odopa, dopamine agonists have been shown to be asso-
ciated with the severity of EDS in some but not all stud-
ies [3, 6, 9, 10].
Hallucinations and REM sleep behavior disorder
(RBD) are also frequently reported, often in combina-
tion, in Parkinsonian disorders including DLB and IPD
[11]. Systematic studies suggest the presence of halluci-
nations in 26–40 % of IPD patients and in up to 62 % of
DLB patients [12–14]. In a recent series RBD was found
by history in 17 % and by polysomnography in 33 % of
IPD patients [15]. The percentage of DLB and MSA pa-
tients with RBD may be as high as 72–100 % [14, 16]. The
coexistence of Parkinsonian disorders with EDS, hallu-
cinations, RBD and ≥2 sleep onset REM periods
(SOREMP) on MSLT has suggested that there is a nar-
colepsy-like pathophysiology in these patients [9, 17].
Considering the high sensitivity and specificity of
low cerebrospinal fluid (CSF) hypocretin-1 levels for the
diagnosis of narcolepsy [18,19], these measurements are
of particular interest in Parkinsonism. Until today, how-
ever, studies on CSF hypocretin-1 in Parkinsonism have
been rare and contradictory with reports of normal [20,
21], low [22], and undetectable levels [23].
The aim of this study was to test by means of a mul-
timodal approach the hypothesis of a common pathway
in the pathophysiology of both Parkinsonism with EDS
and narcolepsy.
Patients and methods
We studied 14 patients (2 women and 12 men; mean age = 69 years,
range 54–82) with Parkinsonism and subjective EDS. Demographic
and clinical characteristics of the patients are summarized in Table 1.
Ten patients were recruited at the University Hospital of Zurich
(Switzerland), and four in the University Hospital “San Raffaele” of
Milan (Italy). Idiopathic Parkinson’s disease and other Parkinsonian
disorders were diagnosed according to international criteria [24, 25].
The severity of Parkinsonism was assessed by the Hoehn and Yahr
Disability scale.
Assessment included a detailed history, a clinical examination,
sleep recordings, and laboratory tests.
■ History
History was obtained by means of standard sleep questionnaires, in-
cluding questions on subjective estimation of EDS (Epworth Sleepi-
ness Score) [26], “sleep attacks” (defined as short, unintended sleep
episodes) and such “REM symptoms” as sleep paralysis, hallucina-
tions, REM-sleep behavior disorder, and cataplexy-like episodes. Di-
agnosis of RBD by history was made according to the International
Classification of Sleep Disorders. Minimal diagnostic criteria include
body or limb movements, associated with dream mentation and at
least one of the following symptoms: (potentially) harmful sleep be-
haviors,dreams that have been reported to be acted out,and sleep dis-
continuation because of sleep behavior [27].A detailed history of cur-
rent medication was also obtained.
■ Clinical examination
A completed neurological examination including a Mini Mental State
Examination [28] was performed in all patients.
■ Sleep recordings
Polysomnography (PSG) was recorded and scored according to inter-
national criteria [29]. Sleep latencies and presence of SOREMP
(epochs of REM sleep occurring within 15 minutes after the first sleep
epoch) were determined on multiple sleep latency tests (MSLT). A
polysomnographic diagnosis of RBD was made in the presence of in-
creased submental EMG tone during REM sleep, in association with
complex motor behaviors such as gesturing, jerking,reaching,punch-
ing, sitting, kicking, laughing, talking and yelling [29].
■ Laboratory tests
Lumbar punctures were performed between 11 a. m. and 4 p. m. with
the patient in a lying position. CSF was immediately frozen at –80° C.
Hypocretin-1 levels in CSF were measured by radio-immunnoassay
(RIA) in crude CSF as previously described [21]. The detection limit
is 20 pg/ml and the intra-assay variability is 4 %. In previous publica-
tions we used published reference levels [19]. Because of the high
inter-assay variability of the RIA kit, we decided for the purpose of
this study to standardize CSF hypocretin-1 levels to own reference
CSF samples, and to compare values with those of a healthy control
group (n = 20, mean age 44 years, range 17–79). Based on our control
group data, we consider CSF hypocretin-1 levels < 320 pg/ml as ab-
normally low. The HLA haplotype DQB1*0602 was determined in five
patients.
All patients gave written informed consent to participate in the
study. The hypocretin-1 results of three patients have been reported
before [30].
Results
The main results of the study are summarized in Table 1.
■ Patients
Diagnoses included idiopathic PD (PD, n = 10), demen-
tia with Lewy bodies (DLB, n = 3), and multisystem atro-
phy (MSA, n = 1). Mean disease duration was 6.3 years
(range 1–16), mean Hoehn&Yahr score 2.2 (range 1–3).
All patients were taking antiparkinsonian drugs (lev-
odopa, n = 8; pergolide, n = 3; cabergoline, n = 3; ropini-
role, n = 1; pramipexole, n = 1), and two patients had
cholinesterase inhibitors. One patient was additionally
treated with clonazepam. All drugs had been taken at
stable doses for at least 1 month before the beginning of
the study.
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■ History
All patients had an Epworth sleepiness score ≥10 (mean
12, range 10–18).“Sleep attacks” were reported by three
patients. Hallucinations were reported by five patients
with idiopathic PD, three patients with DLB, and one pa-
tient with MSA. None of the patients reported sleep
paralysis. Six patients (2 DLB, 4 PD) reported recurrent
falls, but in none were the falls triggered by emotions
(cataplexy-like episodes). In nine patients, history (ob-
tained by the patients or their caregivers/relatives) ful-
filled the clinical criteria for RBD.
■ Sleep recordings
On polysomnography the mean sleep latency (SL) was
27 minutes (range 2–189), slow-wave-sleep (SWS) repre-
sented 16 % of total sleep time (mean, range: 4–39 %)
and REM sleep represented 12 % of total sleep time
(mean, range: 0–24 %) of total sleep time. Two patients
had no REM sleep during polysomnography. REM sleep
behavior disorder was diagnosed polysomnographi-
cally in five patients. Periodic limb movements in sleep
(PLMS > 10) were documented in six patients with a
PLMS-Index ranging from 13/h to 38/h. An abnormal
apnea-hypopnea-index (AHI > 10) was found in seven
patients with an AHI ranging from 11/h to 58/h.
On MSLT the mean sleep latency was 3.5 min (range:
1.1–9.3 min),with a mean sleep latency < 5 minutes in 10
out of 12 patients. Sleep onset REM periods (SOREMP)
were found in patient 9 (in 1 out of 5 naps) and in pa-
tient 14 (in 4 out of 4 naps) (Fig. 1). In a few patients
episodes of atonia and/or rudimentary rapid eye move-
ments were observed during NREM sleep (Fig. 2). In five
patients in whom the information was available, sleep
was perceived subjectively in 18 of 20 naps.
The mean percentage of time “asleep”during actigra-
phy was 40 % (range: 36–43 %), corresponding to 9.6
hours (range 8.6–10.3) per day.
■ Laboratory tests
CSF hypocretin-1 ranged in our controls from 350 to 603
pg/ml (mean 497 pg/ml). Hypocretin-1 levels in CSF
were detectable in all 10 patients tested. The mean
hypocretin-1 level was 480 pg/ml (range 221–654
pg/ml). Patient 4 (221 pg/ml, MSA, disease duration 16
years), and patient 10 (307 pg/ml, IPD, disease duration
3 years) had lower levels than our control group. HLA
DQB1*0602 was positive in two of the five patients
tested.
Discussion
The aim of this study was to test the hypothesis of a nar-
colepsy-like pathophysiology in Parkinsonian patients
with EDS. To our best knowledge, this is the first study
in which a systematic and prospective multimodal ap-
proach including clinical assessment, specific sleep-
wake questionnaires, neurophysiology and CSF
hypocretin-1 measurements has been performed in pa-
tients with Parkinsonism and EDS.
The main results can be summarized as follows:
First, cataplexy-like symptoms and sleep paralysis
were not found in our patients, not even in those report-
Fig. 1 54-year-old male patient (RM) with a 7-year
history of idiopathic Parkinson’s disease and with a
subjective complaint of excessive daytime sleepiness.
Epworth sleepiness score: 11/24. No episodes of sud-
den falling asleep while driving, cataplexy-like
episodes, sleep paralysis, or hallucinations. History of
violent, enacted dreams. Polysomnography: mild
sleep-disordered breathing (apnea-hypopnea
index = 13/hour) and loss of physiological atonia in
REM sleep (Figure). No periodic limb movements in
sleep (PLMS). Multiple sleep latency test: mean sleep
latency of 2.6 minutes, SOREMP in 4 out of 4 naps
143
ing recurrent falls and RBD, in whom an underlying,
common involvement of the pedunculo-pontine nu-
cleus has been postulated [31, 32]. This finding is in ac-
cord with previous reports, in which cataplexy and sleep
paralysis have not been found in PD with EDS and with
or without hallucinations/RBD [11, 20, 33].
Second, sleep onset REM periods (SOREMP) were
observed only in two of our 14 patients (14 %) and in 5
(10 %) out of 52 nap opportunities, respectively. Simi-
larly, Rye et al. found SOREMP in only 10 % of 134 nap
opportunities in IPD patients [1]. Other authors have re-
ported higher frequencies of 29 % (≥ 1 SOREMP during
MSLT on two consecutive days) and 39 % (≥ 1 SOREMP
during a single MSLT) [4, 9]. The reason for these differ-
ences is unclear. Although SOREMP have been reported
to be more frequent in patients with severe EDS [1, 4],
the mean sleep latency found on MSLT in our patients
was not longer than those of previous studies. Differ-
ences in duration/severity of PD, frequency of comor-
bidities, and medication could, however, play a role [32].
Furthermore, four of our patients (one of whom had
SOREMP) had a Parkinsonian disorder other than IPD,
conditions in which the frequency of SOREMP may be
lower than in IPD [34]. Finally, identification of REM
sleep in patients with Parkinsonian disorder is known to
be difficult [35] and differs between sleep centers. We
observed in a few patients dissociated states with atonia
and/or rudimentary eye movements during NREM sleep
2 that did not fulfill the conventional scoring criteria for
REM sleep (Fig. 2).
Third, hypocretin-1 levels in the cerebrospinal fluid
were normal in 8 patients and low (but still > 200 pg/ml)
in two patients. There was no evident association be-
tween hypocretin-1 levels and such features as RBD, hal-
lucinations, Epworth Sleepiness score, and mean sleep
latency on MSLT. It is noteworthy that the hypocretin-1
level was normal also in a single patient with a 7-year
history of IPD, EDS, very short mean sleep latency on
MSLT,and SOREMP in all four naps (Fig. 1). In two other
reports of seven and four patients, respectively [20, 21],
hypocretin-1 levels in IPD patients were also reported to
be within the normal range. In a study reported in ab-
stract form, Japanese authors also found normal levels
in 16 of 19 Parkinsonian patients, and low but still de-
tectable levels in the remaining three patients [22]. Con-
versely, Drouot and colleagues found significantly lower
CSF hypocretin-1 levels in 19 IPD patients when com-
pared with five controls (57 ± 14 vs 199 ± 34 pg/ml). CSF
hypocretin-1 was undetectable in nine of these 19 pa-
tients [21]. Although detailed clinical and neurophysio-
logical assessments are not available in these patients,
differences in clinical characteristics may not be suffi-
cient to explain the discrepancy of results. In fact, pa-
tients with long disease duration and advanced severity
were included in our study as well, and the mean Ep-
worth sleepiness score was similar in both series (12 and
11, respectively). In the French study, hypocretin-1 de-
terminations were performed in ventricular CSF, which
was obtained in the course of operative implantation of
a deep brain stimulator. This different approach may ex-
plain their results.
Fourth, subjective EDS was confirmed by MSLT in
most cases, with a mean sleep latency on MSLT < 5 min
in ten of 12 patients. Mean latencies < 5 minutes have
been found before in 40–50 % of IPD patients with EDS,
in whom however inclusion criteria differed from those
used in this study [4, 9]. It is noteworthy that awareness
of sleep during naps was usually present in our patients,
in whom sleepiness was also associated with abnormal
Epworth sleepiness scores. Conversely, in Parkinsonian
patients with objective but without subjective EDS (as
assessed by Epworth sleepiness score), nap perception
Fig. 2 71-year old male patient (HG) with a 3-year
history of idiopathic Parkinson’s disease and with a
subjective complaint of excessive daytime sleepiness.
Epworth sleepiness score: 10/24. One episode of sud-
den falling asleep (“sleep attack”) while driving led to
a severe car accident. No history of violent, enacted
dreams, cataplexy-like episodes, sleep paralysis or
hallucinations. Polysomnography: severe sleep-
disordered breathing (apnea-hypopnea index =
58/hour, mainly mixed and central events, 16 % of
time oxygen saturation < 90 %). No signs of REM
sleep behavior disorder or periodic limb movements
in sleep. Multiple sleep latency test: mean sleep la-
tency of 1.6 minutes. In the absence of “clear-cut”
sleep-onset REM episodes, a few episodes of muscle
atonia with rudimentary eye movements are ob-
served during NREM sleep 2 (Figure). With CPAP-
treatment (7 cm H2O) normalization of breathing
during sleep. Discontinuation of CPAP after a few
weeks because of mask claustrophobia
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may be more impaired [34]. Our study also confirms
that severe subjective and objective EDS can be a feature
of Parkinsonism at early stages [9]. Two of our patients
had a disease duration of one year.Similarly,Rye et al. re-
ported an 18-year-old unmedicated IPD patient with a
disease duration of two years in whom EDS was accom-
panied by a mean sleep latency on MSLT of 4.6 min (with
SOREMP in one of five naps) [33]. Based on our obser-
vations, we suggest a contribution not only of dopamin-
ergic drugs [4, 10, 36–38], but also of sleep disordered
breathing and periodic limb movements in sleep to EDS
in Parkinsonian disorders. Similarly, in a larger study of
54 IPD patients, Arnulf et al. reported an AHI > 15 in
20 %, and a PLMS-index > 15 in 15 % of her patients [9].
More recently, in a questionnaire survey a history of
heavy snoring was found to correlate with self-reported
EDS in patients with IPD [3]. Treatment of sleep-disor-
dered breathing and PLMS in Parkinsonian patients
with EDS may be warranted before stimulants are tried.
The main limitations of the study are the small sam-
ple size and the inclusion of patients with three different
forms of Parkinson’s syndrome.
In conclusion, our clinical, neurophysiological and
CSF data do not support the hypothesis of a “final com-
mon pathway”in the pathophysiology of narcolepsy and
Parkinsonism with EDS, not even when associated with
hallucinations and REM sleep behavior. Sleep apnea and
PLMS may play a so-far underestimated role in the
pathogenesis of EDS in Parkinsonian disorders.
■ Acknowledgement Mrs S. Brogli and Mrs M.Wacker helped in CSF
hypocretin-1 assessments.
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